A Novel, Simple Scale for Assessing the Symptom Severity of Atrial Fibrillation at the Bedside: the CCS-SAF Scale
Overview
Authors
Affiliations
Background: The severity of symptoms caused by atrial fibrillation (AF) is extremely variable. Quantifying the effect of AF on patient well-being is important but there is no simple, commonly accepted measure of the effect of AF on quality of life (QoL). Current QoL measures are cumbersome and impractical for clinical use.
Objective: To create a simple, concise and readily usable AF severity score to facilitate treatment decisions and physician communication.
Methods: The Canadian Cardiovascular Society (CCS) Severity of Atrial Fibrillation (SAF) Scale is analogous to the CCS Angina Functional Class. The CCS-SAF score is determined using three steps: documentation of possible AF-related symptoms (palpitations, dyspnea, dizziness/syncope, chest pain, weakness/fatigue); determination of symptom-rhythm correlation; and assessment of the effect of these symptoms on patient daily function and QoL. CCS-SAF scores range from 0 (asymptomatic) to 4 (severe impact of symptoms on QoL and activities of daily living). Patients are also categorized by type of AF (paroxysmal versus persistent/permanent). The CCS-SAF Scale will be validated using accepted measures of patient-perceived severity of symptoms and impairment of QoL and will require 'field testing' to ensure its applicability and reproducibility in the clinical setting.
Conclusions: This type of symptom severity scale, like the New York Heart Association Functional Class for heart failure symptoms and the CCS Functional Class for angina symptoms, trades precision and comprehensiveness for simplicity and ease of use at the bedside. A common language to quantify AF severity may help to improve patient care.
Complexity AF score as a novel marker of atrial fibrillation instability.
Lee J, Brower A, Roukoz H, Tolkacheva E Sci Rep. 2024; 14(1):27833.
PMID: 39537673 PMC: 11561269. DOI: 10.1038/s41598-024-76611-7.
Caldarola P, Iaco F, Pugliese F, De Luca L, Fabbri A, Riccio C Eur Heart J Suppl. 2023; 25(Suppl D):D255-D277.
PMID: 37213798 PMC: 10194824. DOI: 10.1093/eurheartjsupp/suad110.
JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.
Ono K, Iwasaki Y, Akao M, Ikeda T, Ishii K, Inden Y J Arrhythm. 2022; 38(6):833-973.
PMID: 36524037 PMC: 9745564. DOI: 10.1002/joa3.12714.
Bates R, Bailey C, Topping A BMJ Open. 2022; 12(11):e065995.
PMID: 36343999 PMC: 9644348. DOI: 10.1136/bmjopen-2022-065995.
Kim J, Park H, Park H, Choi E, Park J, Kim J J Am Heart Assoc. 2022; 11(18):e025956.
PMID: 36073646 PMC: 9683675. DOI: 10.1161/JAHA.122.025956.